Immune-checkpoint inhibitor resistance in cancer treatment: current progress and future directions
C Zhang, C Zhang, H Wang - Cancer letters, 2023 - Elsevier
Cancer treatment has been advanced with the advent of immune checkpoint inhibitors (ICIs)
exemplified by anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed …
exemplified by anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed …
PD-1/PD-L1 and DNA damage response in cancer
M Kciuk, D Kołat, Ż Kałuzińska-Kołat, M Gawrysiak… - Cells, 2023 - mdpi.com
The application of immunotherapy for cancer treatment is rapidly becoming more
widespread. Immunotherapeutic agents are frequently combined with various types of …
widespread. Immunotherapeutic agents are frequently combined with various types of …
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations
S Thavaneswaran, M Kansara, F Lin… - British Journal of …, 2023 - nature.com
Purpose To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib+
durvalumab, O+ D) in patients with advanced solid, predominantly rare cancers harbouring …
durvalumab, O+ D) in patients with advanced solid, predominantly rare cancers harbouring …
Progress in systemic therapy for advanced-stage urothelial carcinoma
R Nadal, BP Valderrama, J Bellmunt - Nature Reviews Clinical …, 2024 - nature.com
Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains incurable,
with 5-year survival rates of approximately 10%. Platinum-based chemotherapy has a major …
with 5-year survival rates of approximately 10%. Platinum-based chemotherapy has a major …
Atezolizumab plus magrolimab, niraparib, or tocilizumab versus atezolizumab monotherapy in platinum-refractory metastatic urothelial carcinoma: a phase Ib/II open …
Purpose: The MORPHEUS platform was designed to identify early efficacy signals and
evaluate the safety of novel immunotherapy combinations across cancer types. The phase …
evaluate the safety of novel immunotherapy combinations across cancer types. The phase …
All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and …
ABSTRACT Background Immune checkpoint inhibitors (ICIs) have been associated with
acute kidney injury (AKI). However, the occurrence rate of ICI-related AKI has not been …
acute kidney injury (AKI). However, the occurrence rate of ICI-related AKI has not been …
Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with …
Q Tang, W Zuo, C Wan, S Xiong, C Xu, C Yuan… - Frontiers in …, 2023 - frontiersin.org
Backgrounds Despite the genomic landscape of urothelial carcinomas (UC) patients,
especially those with UC of bladder (UCB), has been comprehensively delineated and …
especially those with UC of bladder (UCB), has been comprehensively delineated and …
Addition of niraparib to best supportive care as maintenance treatment in patients with advanced urothelial carcinoma whose disease did not progress after first-line …
F Vignani, R Tambaro, U De Giorgi, P Giannatempo… - European urology, 2023 - Elsevier
Background Platinum-based chemotherapy (PBCT) is the standard first-line treatment for
advanced urothelial carcinoma (UC). Potential cross-sensitivity can be hypothesized …
advanced urothelial carcinoma (UC). Potential cross-sensitivity can be hypothesized …
Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma
A Eturi, A Bhasin, KK Zarrabi, WJ Tester - Molecules, 2024 - mdpi.com
Urothelial carcinoma (UC) is the fourth most prevalent cancer amongst males worldwide.
While patients with non-muscle-invasive disease have a favorable prognosis, 25% of UC …
While patients with non-muscle-invasive disease have a favorable prognosis, 25% of UC …
Systemic Treatment-Decision Algorithms in Muscle-Invasive Bladder Cancer: Clinical Complexities and Navigating for Improved Outcomes
M Giles, SJ Crabb - Research and Reports in Urology, 2023 - Taylor & Francis
Muscle-invasive bladder cancer has poor prognosis. If organ confined, it is potentially
curable; however, across all prognostic groups, approximately half of patients will relapse …
curable; however, across all prognostic groups, approximately half of patients will relapse …